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Introduction
Transvenous cardiovascular implantable electronic devices (CIEDs) are widely used due to the effectiveness with which they treat cardiac arrhythmias and the relative ease and safety with which they are implanted. 1, 2 However, an endovascular lead within the right atrium or ventricle represents a foreign body that can promote formation of mobile thrombi that may dislodge to the pulmonary circulation. 3, 4 Although symptomatic pulmonary embolism after pacemaker or defibrillator implantation is uncommon, asymptomatic emboli may be present far more frequently, [4] [5] [6] [7] and endovascular lead-related thrombi are likely under-detected. Utilizing ventilation perfusion scanning, one study showed asymptomatic pulmonary emboli in 15% of patients within two weeks of device implantation without heparin prophylaxis, 8 and at autopsy pulmonary emboli were present in 21% of patients with CIEDs. 6 A study using intracardiac echocardiography at the time of a planned electrophysiologic procedure found mobile thrombi attached to leads in 30% of patients. 9 These thrombi were rarely seen utilizing transthoracic echocardiography (TTE), reflecting their small size. Moreover, the presence of lead-related thrombi was associated with increased pulmonary artery systolic pressure, suggesting subclinical pulmonary embolic events. 9 Elevated pulmonary artery pressures may in turn increase the likelihood of right-to-left shunting across a patent foramen ovale (PFO).
Up to 25% of the population may have a PFO detectable on autopsy, with persistence after birth of a connection between the right and left atria. 10, 11 In patients with elevated rightsided pressures, flow through a PFO provides a mechanism of blood flow from the right heart to the left-sided circulation. In patients with a PFO, endovascular leads may pose a unique hazard since the thrombi that develop on leads may shunt across the PFO to the systemic circulation, resulting in ischemic cerebrovascular events or other systemic thromboembolism. We have patients within two weeks of device implantation without heparin prophylaxis, m 8 a a and nd nd at t t au au auto to tops ps p y y pulmonary emboli were present in 21% of patients with CIEDs. 6 A study using intracardiac ec cho ho hoca ca card rd rdio io iogr g g a aphy hy hy a at t the time of a planned electr r rop op o h h hysiologic pro oce c c du ure re re f found mobile thrombi at tta a ac ched to lead ad ds s in n n 3 3 30% 0% 0% o o of f f pa pa pat ti tien en nts ts ts. . 9 9 T T Th h hese th h hrom m mb bi w w wer er re e r rar re rely ly see een n u u uti il liz izin in ing g g tr tran an anst st stho ho hora a aci c cic c ec cho ho hoca ca card rdio io ogr gr grap aph hy hy ( ( (TT TT TE) E) ), , re r fl fl flec ec cti ti ting ng ng t the he eir ir r s s sm ma mall ll ll s si ize ze ze. . Mo Mo More re reo ov over er er, t th the e e pr pr p e e ese en nce ce e o o of f f le le ead ad ad-re e elat at ted ed hrombi was s as as asso so s ci ci ciat at a ed ed ed w wit it th h h in i i cr cr crea ea e se se sed d pu pu pulm lm lmon on onar ar a y y y ar ar rte tery ry y s s sys ys ysto to toli li lic c c pr pr res es essu su sure re re, , su su s gg gg gges es esti ti ing ng ng subclinica al previously published two case-series on device lead mediated paradoxical thromboembolism 12 and effective management of such high-risk CIED patients with PFO closure to prevent recurrent strokes. 13 Transvenous pacing leads have also been associated with increased risk of systemic thromboembolism in patients with intracardiac shunts. 14 Presently, when an intracardiac shunt, such as an atrial or ventricular septal defect is recognized, endocardial leads are not implanted, and patients are referred for either closure of the shunt or epicardial lead placement. [14] [15] [16] However, whether the presence of a PFO in most CIED recipients increases the risk of clinical strokes or transient ischemic attacks (TIAs) is unknown. Therefore, screening for a PFO is not routinely performed at the time of CIED implantation, and the presence or absence of a PFO does not affect the implant decision or strategy in current clinical practice. In order to test the hypothesis that patients with PFO and right-sided CIED leads are at increased risk for stroke or TIA, we performed a large retrospective study.
Methods

Patient population
All patients who underwent transvenous implantation of an implantable cardioverter-defibrillator or pacemaker at Mayo Clinic, Rochester, Minnesota, between January 1, 2000, and October 25, 2010, were included in the study, and patients' charts reviewed between the last quarter of 2010 and the first quarter of 2011. All patients had authorized review of their medical records for research purposes. Data were de-identified to protect patient confidentiality. Patients were excluded from the analysis if identified as sustaining a possible neurological event during followup but lacked sufficient details in the electronic medical record regarding the symptoms and timing of stroke/TIA, or had an inadequate evaluation to establish a diagnosis and cause of the event. Patients were also excluded if PFO was suspected on echocardiography but not does not affect the implant decision or strategy in current clinical practice. In ord rd de er t t to te te est st st t t the he he hypothesis that patients with PFO and right-sided CIED leads are at increased risk for stroke or TI IA, A, A, w w we e pe pe perf rf rfo o orme me med d d a large retrospective study.
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definitively confirmed, or the diagnosis of PFO was made within 30 days after the occurrence of a stroke/TIA event.
Assessment of PFO and clinical characteristics
All patients receiving implanted devices with endocardial leads at our center routinely have comprehensive TTE performed. Data are prospectively entered into a clinical database with predefined variables, including absence or presence of a PFO. PFO was detected as part of standard protocol for TTE and TEE at Mayo Clinic. This includes the routine use of 2dimentional and color Doppler interrogation of the interatrial septum. We also attempt, in all TTEs, the measurement of right-sided pressures from the tricuspid regurgitant jet velocity. When necessary, use of agitated saline to evaluate for right to left shunting is performed, typically, based on the size of the right atrial chambers and whether there are doubts on the structural integrity of the interatrial septum. If a shunt is visualized or diagnosed but cannot be easily seen at the usual place of a PFO or primum or ASD (primum or secundum) then a TEE to exclude a sinus venosus type ASD is done.
For all study participants, all echocardiogram reports (transthoracic and transesophageal)
were reviewed for the presence of a PFO either by color-flow Doppler and/or intravenous agitated saline "bubble study." The study personnel reviewing echo reports for PFO diagnoses were blinded to the clinical outcomes. This allowed for delineation of the study population into two groups, those with and those without a PFO. Some reports were coded as "possible" or "probable" PFO; in the absence of additional studies that definitively included or excluded PFO, these patients were excluded from the study population. The use of aspirin, warfarin, and clopidogrel was obtained from the electronic medical record in all study patients at three For al all l l st st stud ud dy y y pa pa part rt r ic cip ip ipan an a ts ts s, , a all ll l ech ch choc oc ocar ar ardi di d og og ogra ra ram m m re epo po port rt rts s s (t (t (tra ra rans nsth th thor or orac ac acic ic ic a and nd nd t t tra ra rans ns nses e ophageal) ) ) absence or presence of PFO was determined), and (3) the date of stroke or TIA (in those patients who had neurologic events). Clinical characteristics of the patient population including comorbidities and history of atrial fibrillation (AF) were obtained from the diagnosis codes (ICD-9, HICDA and Berkson Mayo Clinic coding system) for clinical encounters until the time of index device implantation.
Assessment of outcomes
Outcomes data were obtained from a centralized system that contained complete records of all patients treated and followed at Mayo Clinic and its hospitals. These records provide a detailed history and diagnosis for all outpatient encounters, emergency room visits, home and nursing home visits, and inpatient care. 17 We used the diagnosis codes consistent with cerebrovascular events to identify patients with possible stroke or TIA. The electronic medical records were reviewed, and in consultation with a board-certified vascular neurologist (A.A.R.), absence or presence of a documented ischemic stroke or TIA consistent with a cardioembolic etiology was determined and the date of events confirmed. We excluded those events from our stroke/TIA definition in which a definite non-cardioembolic cause for the stroke or TIA was documented, such as intracranial hemorrhage, proximal mobile aortic atheroma, severe ipsilateral carotid stenosis, radiologically proven small subcortical stroke with lacunar presentation, and severe intracranial stenosis in the relevant vessel. Mortality status and date of death were obtained from multiple sources including the Mayo Clinic registration database and Accurint (LexisNexis, Philadelphia, Pennsylvania), an institutionally approved fee-based Internet research and location service.
Statistical methods
Baseline patient demographics were compared between PFO and non-PFO groups using chi-home visits, and inpatient care. 17 We The authors were entirely responsible for study hypothesis development, study design, data collection, data analysis, and manuscript preparation. The study was funded exclusively by Mayo Clinic as part of an implantable device quality practice review. There was no support or input from industry. This study was approved by the Mayo Clinic Institutional Review Board (IRB #10-007582).
Results
Our study included 6075 patients receiving CIED implantations with endocardial leads. Table 2) .
We performed further exploratory analyses to delineate possible subgroups with a different effect of PFO on stroke or TIA compared to the overall population. We stratified the analysis based on age (dichotomized at 65 years), gender, prior history of stroke/TIA, baseline history of AF, baseline aspirin and warfarin use, and thromboembolic risk as measured by Figure 1) . The absence of difference in mortality between groups persisted after adjusting for age, sex, and history of stroke/TIA (hazard ratio: 0.90, 95% CI 0.76-1.06, p=0.20), additional adjustment for history of AF and baseline aspirin and warfarin use (hazard ratio: 0.89, 95% CI 0.75-1.05, p=0.15), and further adjustment using stepwise selection of covariates (hazard ratio: 0.90, 95% CI 0.77-1.07, p=0.23, Table 2 ).
Discussion
In this large, retrospective analysis of endocardial pacemaker and defibrillator recipients, we found a more than 3-fold higher risk of stroke or TIA following device implantation in patients history of AF, baseline aspirin and warfarin use, and thromboembolic risk as me ea a asur ur u ed 1 1 1) . ). ). T T The he he a a abs b b en en ence ce ce o o of f f di di d ff ff ffer er e en en e ce e e i in n n mo mo mort rt rtal a a it t ty y y be be betw tw twee ee een n gr gr grou ou oups ps ps p persisted with a PFO compared to those without a PFO. This dramatically increased risk remained after adjustment for age, sex, previous stroke or TIA, history of AF, and baseline use of aspirin and warfarin. Moreover, the elevated risk persisted over the course of follow-up. This finding contrasts population-based observational studies of PFO and thromboembolism, which failed to find an association between PFO and thromboembolism. 18, 19 However, these studies did not specifically include patients with endovascular pacemakers and defibrillators. The fact that endovascular leads are a nidus for thrombus development 6, 9 and adopt an intracardiac course that frequently is in juxtaposition to the interatrial septum likely accounts for the strong association we observed between PFO and stroke/TIA in device recipients (Figure 3) . This is the first systematic evaluation of risk of systemic embolic events among patients with implanted endocardial pacemaker or defibrillator leads who have an incidentally identified PFO on echocardiography. In current practice, endocardial leads are avoided in patients with unclosed septal defects. 14, 15 Our findings suggest it may be reasonable to extend this strategy to patients with PFO, especially those with significant right-to-left shunt and easily identifiable on routine echocardiography.
PFO has long been postulated as a mechanism for cryptogenic stroke. 20 Although numerous studies have suggested an association between cryptogenic stroke and PFO, [20] [21] [22] [23] [24] [25] an
Olmsted county population-based study did not show an increased risk of stroke or TIA compared to age-and sex-matched controls. 18 Similarly, the PFO in cryptogenic stroke study found no association between PFO and recurrent stroke among patients treated with aspirin or warfarin. 19 The Closure I trial randomized patients with cryptogenic stroke to PFO closure and antiplatelet therapy or to medical therapy alone and found no difference in the rate of recurrent stroke or TIA. 26 Closure I as opposed to the strong association between stroke and PFO in our study. First, Closure I excluded patients with endovascular leads. PFO alone likely poses a significantly lower stroke risk without the concomitant presence of leads to seed thrombus formation in proximity to the interatrial septum. Second, the vast majority of patients with stroke or TIA after enrollment had mechanisms other than paradoxical embolism to account for the event, suggesting that in the device-free cryptogenic stroke population, paradoxical embolus is a relatively uncommon stroke mechanism. Third, Closure I compared an interventional to a medical strategy for stroke prevention; the finding that these had similar efficacy does not exonerate PFO from culpability in systemic embolism. The role of PFO in stroke or TIA is supported by a prospective, observational study that used propensity-score matched comparison groups to show fewer recurrent ischemic events after device closure of PFO. 27 Patient followup was longer (median of 10 years) than in the Closure I trial (2 years).
Additional observations support the mechanistic role of PFO in thromboembolism in patients with endovascular leads. The cumulative incidence curve of stroke or TIA in patients with PFO only begins to diverge from that of non-PFO patients after 6 months post-device implantation (Figure 1A) . This is consistent with a temporal delay as thrombi develop on the leads and right-sided cardiac pressures increase subsequent to subclinical pulmonary embolisms after device implantation, consequently promoting right-to-left blood flow shunting and paradoxical embolism. Previous studies have demonstrated increased pulmonary artery systolic pressure in patients with thrombi found on device leads using intracardiac echocardiography. 9 The fact that these thrombi are small (and thus rarely seen with TTE) may account for the delay in pulmonary artery pressure elevation. Their small size may also account for the lack of increased mortality seen in patients with PFO. Small thrombi may be less likely to occlude a observational study that used propensity-score matched comparison groups to sh how ow ow few ew wer er er ecurrent ischemic events after device closure of PFO. 27 Patient followup was longer (median of 10 0 y y yea ea ar rs rs) ) ) th th than an n in n n th th the e Closure I trial (2 years).
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Our findings have important clinical implications. They suggest it may be reasonable to screen patients undergoing endocardial lead placement to determine whether a PFO is present. In the presence of a significant PFO, concomitant anticoagulation, PFO closure, or epicardial or subcutaneous device placement should be considered. The clinical impact of these findings are large, given that an estimated 25% of the general population has a PFO. 10 In 2009, there were 1 million pacemakers and 328,000 defibrillators implanted worldwide, translating to approximately 332,000 devices in patients with PFOs that year alone. In our study, we found a 8% risk of stroke/TIA at 5 years. Based on these numbers, this would translate to approximately 26,500 people annually with potentially preventable neurological events.
Our results are best interpreted in the context of study limitations. This was a retrospective study and is thus prone to all of the inherent biases associated with such study designs. Specifically, causality and evidence in favor of any clinical interventions cannot be provided. Moreover, any inferences are limited by the possibility of detection and classification biases, both in the clinical course and in the conduct of the study. We sampled antiplatelet and anticoagulant usage at limited points in time, although they varied only to a minor extent between the two groups. Surprisingly, we did not see any attenuation of the increased stroke/TIA risk among patients with PFO with baseline antiplatelet or anticoagulant use, and it is not clear if this was due to lack of efficacy of such therapies or methodological pitfalls like missing or time variable data, confounding, or ascertainment bias. misclassification bias towards null, there was a significant difference in stroke or TIA during followup, further supporting the magnitude of the interaction between endocardial leads and PFO. In any case, our study shows that the "more apparent" PFOs that were identified without a protocolled method to evaluate for their presence were attributable towards a substantial increase in risk of embolic ischemic events.
In conclusion, in patients with endovascular pacemaker or defibrillator leads, the presence of a PFO is independently associated with a significantly increased risk of stroke or TIA, which persists during long-term followup. Lead thrombi and paradoxical embolism likely 
